Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 2834

Novel use of senicapoc to treat or prevent malaria

Inventors: Venee Tubman

Invention Types: Therapeutics

Research Areas: Infectious Disease

Keywords: New Indication/Use, Small Molecule/Drug, Target

For More Information Contact:  Meyer, Abbie

 

Invention Description:

Malaria, which causes about half a million deaths and infects 198 million people annually, is difficult to control and prevent, and is a growing threat world-wide. Mono-therapy can lead to drug resistance to known anti-malarial agents. There is a need for novel antimalarial drugs with new targets.


Dr. Tubman and colleagues have conceived of a novel use for senicapoc, a Gardos-channel (calcium-activated potassium channel) inhibitor developed for sickle cell disease which as now been repurposed for development into an antimalarial agent. Red cell volume regulation is critical to the pathology of the parasites that cause malaria since plasmodium depends upon ion flow across the host membrane for growth. Cellular volume regulation also modulates the host defense against malaria infection and parasite growth is impaired in dense, dehydrated erythrocytes. Senicapoc and similar compounds may function as antimalarial agent by preventing parasite growth since they inhibit erythrocyte volume regulation.

Applications:

A novel class of antimalarial agents with a promising safety profile

Competitive Advantages:

• A well-studied and well-tolerated safe drug in human and animal studies for sickle cell disease that exhibits antimalarial activity.

• A novel mechanism of action with a new use for malaria.

• Effectively impairs parasite growth in vivo and in vitro.

• Rapidly kills parasites in the latter stages of the asexual cycle.

• Simple chemical structural changes provide congeners with similar antimalarial activity.

Business Opportunity:

Licensing agreement or sponsored research.

Key Publications: Venee N. Tubman, Pedro Mejia, Boris E. Shmukler, Amy K. Bei, Seth L. Alper, James R. Mitchell, Carlo Brugnara, Manoj T. Duraisingh; 2016 The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity. Antimicrobial Agents and Chemotherapy 60, 613-616

IPStatus: Pat. Pend.